Qualigen Therapeutics Stockholders approve all proposals, leading to the rebranding of the company as AIxCrypto Holdings, Inc. with the ticker symbol AIXC.
Faraday Future will become the majority and controlling shareholder of Qualigen Therapeutics, supporting a strategic transformation into the AI × Web3 era.
The renaming and ticker activation ceremony at Nasdaq Headquarters in New York on November 20 will unveil AIxCrypto's new business model and ecosystem structure.
Transition to AIxCrypto Holdings
Approved proposals confirm Faraday Future as the majority shareholder, leading to the company's transition to AIxCrypto Holdings, Inc.
New Ticker Symbol AIXC
The new ticker symbol AIXC will represent AIxCrypto Holdings, signaling a shift towards AI × Web3 technologies.
Strategic Transformation Plan
The event on November 20 will introduce AIxCrypto's business framework, ecosystem architecture, and three-year development roadmap.
- The transition aims to establish a reciprocal strategic enablement dynamic between AIxCrypto and Faraday Future, focusing on innovation and long-term value creation.
- The evolution from biotechnology to Web3-driven decentralized...
The renaming of Qualigen Therapeutics to AIxCrypto Holdings signifies a strategic shift towards decentralized artificial intelligence technology and Web3 integration. This transformation positions the company as a leader in the AI × Web3 era, aligning with innovative growth strategies and ecosystem development.